Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Income from Continuing Operations: 2022-2024

Historic Income from Continuing Operations for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to -$88.7 million.

  • Stoke Therapeutics' Income from Continuing Operations fell 45.09% to -$38.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $40.4 million, marking a year-over-year increase of 138.26%. This contributed to the annual value of -$88.7 million for FY2024, which is 15.38% up from last year.
  • According to the latest figures from FY2024, Stoke Therapeutics' Income from Continuing Operations is -$88.7 million, which was up 15.38% from -$104.9 million recorded in FY2023.
  • Over the past 5 years, Stoke Therapeutics' Income from Continuing Operations peaked at -$88.7 million during FY2024, and registered a low of -$104.9 million during FY2023.
  • Its 3-year average for Income from Continuing Operations is -$98.3 million, with a median of -$101.2 million in 2022.
  • As far as peak fluctuations go, Stoke Therapeutics' Income from Continuing Operations fell by 3.59% in 2023, and later climbed by 15.38% in 2024.
  • Stoke Therapeutics' Income from Continuing Operations (Yearly) stood at -$101.2 million in 2022, then decreased by 3.59% to -$104.9 million in 2023, then climbed by 15.38% to -$88.7 million in 2024.